key: cord-0987666-xcbgt472 authors: McBride, Jeffrey D.; Narang, Jatin; Simonds, Robert; Agrawal, Shruti; Rodriguez, E. Rene; Tan, Carmela D.; Baldwin, William M.; Dvorina, Nina; Krywanczyk, Alison R.; Fernandez, Anthony P. title: Development of sacral/buttock retiform purpura as an ominous presenting sign of COVID‐19 and clinical and histopathologic evolution during severe disease course date: 2021-05-11 journal: J Cutan Pathol DOI: 10.1111/cup.14038 sha: ff2ec5d5e1ce0265b9d6000b2fb07e004d9d5dec doc_id: 987666 cord_uid: xcbgt472 Retiform purpura has been described as a relatively frequent cutaneous finding in patients with coronavirus disease 2019 (COVID‐19). The etiology is hypothesized to be related to thrombotic vasculopathy based on lesional biopsy specimen findings, but the pathogenesis of the vasculopathy is not completely understood. Here, we present a case of a retiform purpuric patch on the sacrum/buttocks in a hospitalized patient prior to subsequent diagnosis of COVID‐19 and an eventual fatal disease course. Two lesional biopsy specimens at different time points in the disease course revealed thrombotic vasculopathy, despite therapeutic anticoagulation. Detailed histopathologic evaluation using immunohistochemical markers suggest the etiology of the vasculopathy involves both persistent complement activation and platelet aggregation, which possibly promote ongoing thrombus formation. This case highlights that sacral/buttock retiform purpuric patches may be a presenting sign of infection with SARS‐CoV‐2 virus and may represent an ominous sign supporting a future severe disease course. In addition, biopsy specimen findings at separate time points demonstrate that cutaneous vasculopathy may persist despite adequate systemic anticoagulation, possibly due to the combination of persistent complement and platelet activation. Finally, occlusive thrombi in sacral/buttock retiform purpuric patches may contribute to future ulceration and significant cutaneous morbidity in patients who survive COVID‐19. A 66-year-old woman with hypertension, diabetes, end-stage renal disease requiring hemodialysis, chronic obstructive pulmonary disease (COPD) and coronary artery disease was hospitalized at our institution for an ST-elevation myocardial infarction. She had successful coronary artery stent placement, but developed ulnar artery occlusion secondary to balloon angioplasty and was anticoagulated with clopidogrel 75 mg daily, aspirin 81 mg daily, and a continuous heparin infusion (500 units/h). On Day 5 of hospitalization, she complained of buttock pain and was noted to have a new, nonindurated, retiform purpuric patch involving her buttocks ( Figure 1B ). On Day 6 of hospitalization, the dermatology team was consulted due to concern for calciphylaxis. During examination, the patient was comfortable, talkative, and able to easily move herself. A lesional punch biopsy of the purpuric patch was performed. The same day, the patient underwent a nasal swab test for COVID-19, as she developed a low-grade fever and had recently been in close contact with two sons newly diagnosed with Over the next few days, the patient remained intubated and the purpuric sacral/buttocks patch worsened. Because of this progression, the dermatology team was again consulted on Day 12 to evaluate for possible calciphylaxis. The patient's D-dimer levels increased from 5140 ng/mL (normal <500 ng/mL fibrinogen-equivalent units on the day of biopsy to 11 740 ng/mL 3 days later (on Day 10 of hospitalization) ( Table 1 ). On examination, the purpuric patch was notably more violaceous and had progressed to superficial ulceration in some areas F I G U R E 1 Evolution of the patient's sacral/buttocks retiform purpuric patch during her COVID-19 disease course. A, Baseline sacral skin photograph documented per standard protocol by the wound care team after consultation for intergluteal hyperpigmentation. The wound care team assessed that the hyperpigmentation was normal and there was no evidence of pressure injury or purpura. B, Retiform purpuric patch on Day 6 of hospitalization at time of initial dermatology evaluation; C, worsening of the purpuric patch with superficial ulceration on Day 12 of hospitalization at time of second dermatology evaluation. Arrows in panels B and C indicate branching retiform purpuric areas at the periphery of the wound edge, indicative of a thromboembolic process an activated partial thromboplastin time (aPTT) >139 seconds (target on anticoagulation ≥100 seconds) and normal platelet levels (Table 1) . On Day 14, after failing extubation, the patient required reintubation and vasopressor support. On Day 15, the patient's D-dimer levels increased to 34 100 ng/mL, she developed bradycardia and hypotension unresponsive to vasopressors, and expired. F I G U R E 2 Histopathologic findings of a lesional biopsy specimen on hospitalization Day 6. Of note, biopsies from Days 6 and 12 revealed the same features: A, H&E sections reveal epidermal necrosis and papillary dermal vessels with intraluminal thrombi despite current therapeutic anticoagulation (Â200). B, A deep dermal/subcutaneous vessel with extensive thrombosis admixed with inflammatory cell debris (Â400). C, Phosphotungstic acid hematoxylin (PTAH) stain highlights fibrin-rich thrombi staining blue within the vessels (Â400). Platelet markers, D, CD61 (Â400) and, E, CD41 (Â400) reveal platelet aggregation within vessel lumina, with predominant aggregation at the vessel periphery. F, Complement split product C4d is diffusely present along the walls of vessel lumina (Â400) T A B L E 1 Hematologic laboratory data throughout patient's hospital course C4d is a complement product representative of the classical/lectin pathway. 11 In addition, elevated C4d levels have been associated with increased oxygen demand in COVID-19 patients. 11 Magro et al previously demonstrated C5b-9 and C4d in lung and cutaneous microvasculature of five COVID-19 patients. 3 As C4d is a sensitive indicator of complement activation, its persistent deposition on endothelial cells in our patient's biopsies may indicate continued complement activity that amplifies thrombus formation. 12 This could explain why thromboses persisted in our patient's biopsies over time and despite therapeutic anticoagulation. Furthermore, the presence of SARS-CoV-2 RNA in platelets has been previously documented. 13 Although we were not able to evaluate for SARS-CoV-2 RNA in our patient's platelets, if present it may have contributed to persistent thromboses in the face of therapeutic anticoagulation. In contrast to reports highlighting fibrin-rich clots without significant platelet aggregation, our patient's vasculopathy was associated with both intravascular fibrin-rich thrombi and platelet aggregations. 4 To our knowledge, platelet aggregations within thrombosed cutaneous vessels in COVID-19 patients have not yet been reported. Although complement activation has been a focus of study, there is accumulating evidence that platelet dysfunction also plays a role in COVID-19 coagulopathy. 14 Platelets in patients with severe COVID-19 are hyperactivated, contribute to the degree of systemic inflammation, and have increased pro-thrombotic potential. 12 Also, platelet aggregation appears to occur at lower thrombin levels than expected in COVID-19 patients. 12 and catastrophic antiphospholid antibody syndrome (APS). 16, 17 Coagulopathy in APS results from the presence of autoantibodies that recognize phospholipid-binding proteins (such as beta-2-glycoprotein) alone or in combination with anionic phospholipids (such as cardiolipin). 17 This antibody-antigen interaction is thought to activate platelets and endothelial cells via mechanisms similarly proposed in patients with severe COVID-19. 16, 17 In both APS and severe COVID-19-related thrombosis, tissue factor is elevated and thought to play an important role in promoting the extrinsic arm of the coagulation cascade. 16, 17 In patients similar to ours, it may be valuable in the future to assess whether von Willebrand factor and thrombomodulin expression is altered, as mortality in COVID-19 patients has been found to significantly correlate with levels of both. 18 It is also noteworthy that our patient developed thromboses despite being fully anticoagulated. The development of microvascular and macrovascular thromboses in COVID-19 patients is well established, leading to efforts in developing optimal prophylactic antithrombotic regimens. 19 patients with sacral/buttocks purpura to those from biopsy specimens from a control cohort with pressure ulcers to explore whether unique features exist that may reliably distinguish between potential etiologies. We hope to report results of this study in the near future. In summary, we report development of sacral/buttock retiform purpura on the buttocks as an ominous presenting sign of severe COVID-19. Clinicians should be highly suspicious of COVID-19 if this cutaneous abnormality is observed. Our case further supports retiform purpuric patches are secondary to thrombotic vasculopathy that is resistant to therapeutic anticoagulation. Immunohistochemical findings suggest this vasculopathy is reminiscent of complementmediated TMA syndromes, as may be seen in severe SLE and APS, as opposed to DIC. Aligning with our patient's clinical course, anticoagulation is known to be insufficient in TMA syndromes related to SLE and APS. 30 Identifying sacral/buttocks retiform purpura and its possible association with severe COVID-19 course may allow aggressive early treatment that minimizes end-organ damage and death. Additional work to better understand the contributions of complement activation and platelet dysfunction in the pathogenesis of COVID-19-associated coagulopathy is needed before optimally effective treatments can be developed. Furthermore, research is needed to determine the role of pressure-induced injury in sacral/buttocks purpura that arises after COVID-19 diagnosis and a prolonged bedbound state. Retiform purpura as a dermatological sign of coronavirus disease 2019 (COVID-19) coagulopathy The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases The differing pathophysiologies that underlie COVID-19 associated perniosis and thrombotic retiform purpura: a case series Spectrum of clinicopathologic findings in COVID-19-induced skin lesions: demonstration of direct viral infection of the endothelial cells Interplay between SARS-CoV-2 and the type I interferon response Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Complement as a target in COVID-19? Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients Pros and cons for C4d as a biomarker Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19 Platelets and COVID-19: inflammation, hyperactivation and additional questions Diagnosis, management, and pathophysiology of arterial and venous thrombosis in COVID-19 Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients Antiphospholipid syndrome: multiple mechanisms Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, crosssectional study COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: a structured summary of a study protocol for a randomised controlled trial Coagulation status and venous thromboembolism risk in African Americans: a potential risk factor in COVID-19 Large sacral/buttocks ulcerations in the setting of coagulopathy: a case series establishing the skin as a target organ of significant damage and potential morbidity in patients with severe COVID-19 Purpuric ulcers associated with COVID-19 infection: a case-series Histopathology of the decubitus ulcer Morphological characteristics of the dermal papillae in the development of pressure sores The decubitus ulcer: many questions but few definitive answers Pressure ulcer tissue histology: an appraisal of current knowledge Pressure (decubitus) ulcer: variation in histopathology-a light and electron microscope study Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications We would like to thank Janine Sot, MBA, for her expertise in preparing the figures accompanying this manuscript. The work has no formal funding sources. The data that support the findings of this study are available from the corresponding author upon reasonable request.